Spotlight Stories

  1. Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper 7/1/2022

    Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline data to regulatory filing in 70 days. 

  2. 3 Approaches For Developing Better Drugs To Treat Brain Disorders 6/1/2022

    Three organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments for intractable brain disorders.

  3. Leveling Up By Challenging Assumptions 6/1/2022

    An outspoken champion of gender equity and diversity in the workplace, Arcellx CEO Rami Elghandour aims to put the company’s controllable CAR-T therapies on the cover of Time magazine.

  4. CoCrystal's Co-CEOs 6/1/2022

    Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.

  5. A New Model For A New Era Of Psychedelic Therapy 5/2/2022

    MAPS Public Benefit Corporation hopes to kick off the next golden age of psychedelic therapy with the potential FDA approval of its MDMA candidate for PTSD.

  6. Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma's CEO Bruce Cozadd 5/2/2022

    A Q&A with Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, on the $7.2 billion acquisition, integration, and future of cannabis drug pioneer GW Pharmaceuticals.

  7. Platforms To Pipelines: Part 2 5/2/2022

    In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.

  8. Thinking Differently About Rare Disease Therapies 4/1/2022

    As Ultragenyx continues building its new gene therapy manufacturing facility, CEO and president Dr. Emil Kakkis talks about his unique outlook on the rare disease space.

  9. A Q&A With A Venture Capitalist/Genetic Medicines Executive 4/1/2022

    Small biotech companies can improve their fundraising prowess, despite choppy market conditions, by avoiding a few common mistakes. Telling a good story is the first step.

  10. Beyond Profits To Biopharma Innovation 4/1/2022

    What if, for certain ambitious but traditionally underfunded areas needing innovation, a startup could achieve its ends without the usual for-profit incentives?